Geftinat 250Mg Tablet is an anticancer medicine which is used in the treatment of cancer of the lungs. It should only be used under the supervision of a qualified physician. This medicine is not recommended for use in patients with lung and liver diseases.
Gefitinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer.
Gefitinib may also be prescribed for other conditions as determined by the doctor.
gefitinib dose tablets 250mg are used as first line therapy to treat locally advanced (stage III) or metastatic (stage IV) non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and grows more slowly than small cell lung cancer (SCLC). NSCLC is associated with a mutation in the gene for Epidermal Growth Factor Receptor (EGFR) in a proportion of these cancers1, 2 specifically those with a cell type of adenocarcinoma3. Epidermal Growth Factor is a growth factor that is found in many normal tissues and controls cell growth. However, in some types of cancer including NSLC, its action is uncontrolled, allowing cells to continue to grow and spread. For Geftinat tablets 250mg to be an effective treatment for NSCLC a specific type of gene mutation should be identified and present in the tumour cells. In these cases of treatment of NSCLC with Geftinat tablets 250mg is highly effective in preventing disease progression.
gefitinib tablets ip tablets 250mg contain gefitinib a potent inhibitor of tyrosine kinase (TK), an enzyme that phosphorylates a protein inside a cell (transfers a phosphate from ATP to a protein inside the cell), which is the way many cell processes are regulated.
EGF stimulates cell growth, proliferation and differentiation in normal cells. It acts by binding with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors.
geftinat 250 mg side effects buy online Safe Tablet can result in some major as well as minor. Major gefitinib side effects Tablet side effects that you may experience are
- Abdominal pain
- Loss of appetite
- Eye irritation
- Blurred vision
- Clay-coloured stools
- Discolouration of urine
- Skin rash
Skin reactions – Patients receiving gefitinib drug Tablet have experienced severe skin reactions like toxic epidermal necrolysis, Stevens Johnson syndrome, and erythema multiforme. Close monitoring of symptoms like change in color of the skin, skin rashes, itching, blistering, etc. is necessary while receiving this medicine. Any such symptoms should be reported to the doctor on priority. The treatment should be discontinued if these symptoms appear.
Pregnancy – This medicine is not recommended for use in pregnant women.
Breast-feeding – This medicine is not recommended for use in breastfeeding women unless absolutely necessary. If this medicine is prescribed, your doctor will advise you to discontinue breastfeeding.
Store Geftinat tablet at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light. Protect from moisture.